Vis enkel innførsel

dc.contributor.authorVinnes, Erik Wilhelm
dc.contributor.authorSkarbø, Birthe Rochlenge Skarbø
dc.contributor.authorWentzel-Larsen, Tore
dc.contributor.authorSylte, Marit Sverresdotter
dc.contributor.authorApelseth, Torunn Oveland
dc.date.accessioned2023-01-24T08:38:50Z
dc.date.available2023-01-24T08:38:50Z
dc.date.created2022-12-16T16:42:49Z
dc.date.issued2023
dc.identifier.issn2050-4527
dc.identifier.urihttps://hdl.handle.net/11250/3045675
dc.description.abstractBackground It is important and expected of laboratories to provide updated reference intervals to the clinician. As no recent publications report adult total IgE reference intervals on a Scandinavian population, the aim of our study was therefore to provide an estimate on healthy Norweigian adults. Methods A reference interval study was conducted in accordance to CLSI guidelines. Samples were collected from n = 252 presumably healthy adult participants enrolled through the regional blood donation program. Total IgE measurements were performed on the ImmunoCAPTM platform (Thermo Fisher Diagnostics) traceable to the WHO-reference standard (75/502) for total IgE measurements. Results An upper 95% total IgE reference limit was estimated to 302 kU/L (90% CI 177–388 kU/L), and the 97.5% percentile was estimated to 391 kU/L (90% CI 344–560 kU/L). No significant differences were found between participants who self-reported having an allergic disease and participants who did not self-report having an allergic disease. Conclusion Our results and other recent publications find markedly higher values than adult reference intervals established four decades ago which still remain widely used by clinical laboratories. We therefore recommend total IgE reference intervals should be critically reviewed and updated.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleUpdated total IgE reference intervals in Norwegian adultsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Authorsen_US
dc.source.articlenumbere751en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1002/iid3.751
dc.identifier.cristin2094593
dc.source.journalImmunity, Inflammation and Diseaseen_US
dc.identifier.citationImmunity, Inflammation and Disease. 2023, 11 (1), e751.en_US
dc.source.volume11en_US
dc.source.issue1en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal